These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

777 related items for PubMed ID: 32795349

  • 1. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
    Jiang H, Zheng Y, Qian J, Mao C, Xu X, Li N, Xiao C, Wang H, Teng L, Zhou H, Wang S, Zhu D, Peng B, Shen L, Xu N.
    BMC Cancer; 2020 Aug 14; 20(1):760. PubMed ID: 32795349
    [Abstract] [Full Text] [Related]

  • 2. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.
    Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, Shu Y, Li J, Zhao J, Pan H, Luo S, Qin Y, Guo Q, Bai Y, Ling Y, Yang J, Yan Z, Yang L, Tang Y, He Y, Zhang L, Liang X, Niu Z, Zhang J, Mao Y, Guo Y, Peng B, Li Z, Liu Y, Wang Y, Zhou H, ORIENT-16 Investigators.
    JAMA; 2023 Dec 05; 330(21):2064-2074. PubMed ID: 38051328
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
    Jiang H, Yu X, Li N, Kong M, Ma Z, Zhou D, Wang W, Wang H, Wang H, He K, Li Z, Lu Y, Zhang J, Zhao K, Zhang Y, Xu N, Li Z, Liu Y, Wang Y, Wang Y, Teng L.
    J Immunother Cancer; 2022 Mar 05; 10(3):. PubMed ID: 35296556
    [Abstract] [Full Text] [Related]

  • 4. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
    Xu J, Bai Y, Xu N, Li E, Wang B, Wang J, Li X, Wang X, Yuan X.
    Clin Cancer Res; 2020 Sep 01; 26(17):4542-4550. PubMed ID: 32561664
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).
    Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, Cho H, Kang WK, Komatsu Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, Azuma M, Chen LT, Kang YK.
    Ann Oncol; 2019 Feb 01; 30(2):250-258. PubMed ID: 30566590
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study.
    Li N, Li Z, Fu Q, Zhang B, Zhang J, Wan XB, Lu CM, Wang JB, Deng WY, Ma YJ, Bie LY, Wang MY, Li J, Xia QX, Wei C, Luo SX.
    Int J Surg; 2024 Apr 01; 110(4):2071-2084. PubMed ID: 38320099
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
    Kawazoe A, Yamaguchi K, Yasui H, Negoro Y, Azuma M, Amagai K, Hara H, Baba H, Tsuda M, Hosaka H, Kawakami H, Oshima T, Omuro Y, Machida N, Esaki T, Yoshida K, Nishina T, Komatsu Y, Han SR, Shiratori S, Shitara K.
    Eur J Cancer; 2020 Apr 01; 129():97-106. PubMed ID: 32145474
    [Abstract] [Full Text] [Related]

  • 8. Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer.
    Petrioli R, Francini E, Cherri S, Marrelli D, Rovello F, Fiaschi AI, Miano ST, Savelli V, Calomino N, Farsi M, Vernillo R, Francini G.
    Anticancer Drugs; 2020 Mar 01; 31(3):292-297. PubMed ID: 31850915
    [Abstract] [Full Text] [Related]

  • 9. Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study.
    Jiang Z, Zhou A, Sun Y, Zhang W.
    BMC Cancer; 2022 Mar 09; 22(1):253. PubMed ID: 35264150
    [Abstract] [Full Text] [Related]

  • 10. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, Tejani MA, Udrea AA, Tehfe M, De Vita F, Turkington C, Tang R, Ang A, Zhang Y, Hoang T, Sidhu R, Cunningham D.
    Lancet Oncol; 2017 Nov 09; 18(11):1467-1482. PubMed ID: 28958504
    [Abstract] [Full Text] [Related]

  • 11. Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial.
    Xu J, Xu N, Bai Y, Liu R, Mao C, Sui H, Wang X, Jiang Q, Dou Y.
    Oncoimmunology; 2020 Dec 31; 10(1):1864908. PubMed ID: 33457083
    [Abstract] [Full Text] [Related]

  • 12. A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
    Lui A, Mulder K, Brezden-Masley C, Vickers M, Monzon J, Kennecke H, Goel R, Vos L, Ghosh S, Marginean H, Fields A, Maroun J, Spratlin J.
    Invest New Drugs; 2018 Aug 31; 36(4):674-682. PubMed ID: 29725881
    [Abstract] [Full Text] [Related]

  • 13. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, Nirni S, Lakshmaiah K, Thomas A, Jiang Y, Zhu M, Tang R, Anderson A, Dubey S, Oliner KS, Loh E.
    Lancet Oncol; 2014 Aug 31; 15(9):1007-18. PubMed ID: 24965569
    [Abstract] [Full Text] [Related]

  • 14. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up.
    Rosenberg AJ, Rademaker A, Hochster HS, Ryan T, Hensing T, Shankaran V, Baddi L, Mahalingam D, Mulcahy MF, Benson AB.
    Oncologist; 2019 Aug 31; 24(8):1039-e642. PubMed ID: 31138725
    [No Abstract] [Full Text] [Related]

  • 15. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
    Janjigian YY, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C, Chou JF, Segal MF, Simmons MZ, Momtaz P, Shcherba M, Ku GY, Zervoudakis A, Won ES, Kelsen DP, Ilson DH, Nagy RJ, Lanman RB, Ptashkin RN, Donoghue MTA, Capanu M, Taylor BS, Solit DB, Schultz N, Hechtman JF.
    Lancet Oncol; 2020 Jun 31; 21(6):821-831. PubMed ID: 32437664
    [Abstract] [Full Text] [Related]

  • 16. KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.
    Tabernero J, Bang YJ, Van Cutsem E, Fuchs CS, Janjigian YY, Bhagia P, Li K, Adelberg D, Qin SK.
    Future Oncol; 2021 Aug 31; 17(22):2847-2855. PubMed ID: 33975465
    [Abstract] [Full Text] [Related]

  • 17. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.
    Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, Zimina AV, Bai Y, Shi J, Lee KW, Wang J, Poddubskaya E, Pan H, Rha SY, Zhang R, Hirano H, Spigel D, Yamaguchi K, Chao Y, Wyrwicz L, Disel U, Cid RP, Fornaro L, Evesque L, Wang H, Xu Y, Li J, Sheng T, Yang S, Li L, Moehler M, Xu RH, RATIONALE-305 Investigators.
    BMJ; 2024 May 28; 385():e078876. PubMed ID: 38806195
    [Abstract] [Full Text] [Related]

  • 18. Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
    Peng Z, Wei J, Wang F, Ying J, Deng Y, Gu K, Cheng Y, Yuan X, Xiao J, Tai Y, Wang L, Zou J, Zhang Y, Shen L.
    Clin Cancer Res; 2021 Jun 01; 27(11):3069-3078. PubMed ID: 33766817
    [Abstract] [Full Text] [Related]

  • 19. Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma.
    Manji GA, Lee S, Del Portillo A, May M, Ana SS, Alouani E, Sender N, Negri T, Gautier K, Ge L, Fan W, Xie M, Sethi A, Schrope B, Tan AC, Park H, Oberstein PE, Shah MA, Raufi AG.
    JAMA Oncol; 2023 Dec 01; 9(12):1702-1707. PubMed ID: 37856106
    [Abstract] [Full Text] [Related]

  • 20. A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.
    Uronis HE, Bendell JC, Altomare I, Blobe GC, Hsu SD, Morse MA, Pang H, Zafar SY, Conkling P, Favaro J, Arrowood CC, Cushman SM, Meadows KL, Brady JC, Nixon AB, Hurwitz HI.
    Oncologist; 2013 Dec 01; 18(3):271-2. PubMed ID: 23485624
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.